RoosterBio-Sartorius partnership to expand cell, gene therapy manufacturing into South Korea

 KUALA LUMPUR, Dec 3 -- RoosterBio Inc, a leading supplier of innovative cellular therapy bioprocess tools and scalable manufacturing solutions for regenerative medicine, has entered into an exclusive agency agreement with Sartorius Korea Biotech, a subsidiary of the Sartorius Group.

This strategic partnership combines Sartorius’ proven expertise in providing high-calibre bioprocess testing, technical and customer services to the local South Korean market, as well as its global reach, and RoosterBio’s advanced platform of RUO and cGMP-grade human mesenchymal stem/stromal cell (hMSC) working cell banks, optimised paired media, and hMSC bioprocess systems.

This winning combination sets the stage for accelerating the development of new, effective medical treatments and expands RoosterBio’s footprint into Asia, especially in South Korea.

“South Korea is a pre-eminent innovator in hMSCs, and the South Korean biotech ecosystem has been flourishing according to every measure of growth.

“One of the first MSC therapies was developed in Korea, clearing an entirely new path to treat previously incurable diseases,” said RoosterBio Chief Executive Officer, Margot Connor in a statement.

Under the terms of the agreement, Sartorius Korea Biotech - a leading international partner of the biopharmaceutical and life science research sectors - will engage with its customers as an exclusive agent for RoosterBio to facilitate sales operations and increase the market potential for RoosterBio products on an exclusive basis in South Korea.

“RoosterBio’s commercialised product systems standardise hMSC manufacturing to remove years of time and millions of dollars from the timeline of traditional mesenchymal cell therapeutic product development and clinical translation efforts,” said Sartorius Korea Biotech Managing Director, Duck Sang Kim.

For details, visit www.roosterbio.com.

-- BERNAMA